PARDES BIOSCIENCES, INC.

Pardes Biosciences, Inc. (Nasdaq: PRDS) is a clinical-stage biopharmaceutical company focused on developing antiviral therapeutics, with its lead program targeting SARS-CoV-2. The company became publicly traded through a merger with LifeSci Acquisition 2 Corp, a blank-check vehicle sponsored by LifeSci Capital that completed its IPO in 2021. The business combination closed in early 2022, bringing Pardes to market under the PRDS ticker. The June 2022 Form 8-K filing, carrying accession number 0000950170-22-011471, represents one of several current reports filed by the company in the period following the de-SPAC transaction. Sign up on SpacDesk for full filing history, transaction timelines, and real-time data on PRDS and hundreds of other SPAC-related companies.